Medicine Overview
Adult Dose
| Clinical Information | Administration Information |
|---|---|
|
Indication: Mantle Cell Lymphoma Condition: Previously untreated |
Dose: Intravenous Injection – 1.3 mg/m² Frequency: twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12 to 21) Duration: six 3-week cycles; may continue for 8 cycles if the response is first seen at cycle 6 Note: Give with rituximab 375 mg/m² intravenous, cyclophosphamide 750 mg/m² intravenous, and doxorubicin 50 mg/m² intravenous on day 1, plus prednisone 100 mg/m² intravenous on days 1-5 |
|
Indication: Mantle Cell Lymphoma Condition: Relapsed |
Dose: Intravenous or Subcutaneous Injection – 1.3 mg/m²/dose Frequency: twice weekly for 2 weeks (days 1, 4, 8, 11) followed by a 10-day rest period (days 12 to 21) Note: Therapy extending beyond 8 cycles: Give standard schedule |
Child Dose
| Clinical Information | Administration Information |
|---|---|
|
Age: Pediatric |
Dose: Not applicable – No approved pediatric dosage available Note: No approved pediatric dosage available |
Renal Dose
| Clinical Information | Administration Information |
|---|---|
|
Condition: Renal Impairment |
Dose: Injection – No starting dosage adjustment recommended Note: In patients requiring dialysis, Bortezomib Injection should be administered after the dialysis procedure |
Administration
- Given as IV or subcutaneous injection
- Must be administered by healthcare professionals
Side Effect
- Asthenia (61-65%)
- Nausea (61-65%)
- Diarrhea (51-55%)
- Anorexia (41-45%)
- Constipation (41-45%)
- Thrombocytopenia (41-45%)
- Peripheral neuropathy (IV 16-41%, SC 6-24%)
- Pyrexia (36-40%)
- Vomiting (36-40%)
- Anemia (31-35%)
- Arthralgia (26-30%)
- Headache (26-30%)
- Insomnia (26-30%)
- Limb pain (26-30%)
- Dizziness (21-25%)
- Dyspnea (21-25%)
- Edema (21-25%)
- Neutropenia (21-25%)
- Paresthesia (21-25%)
- Rash (21-25%)
- Cough (15-20%)
- Dehydration (15-20%)
- URI (15-20%)
- Rigors, grade 4 toxicity (10-15%)
Drug Interaction
Drug Interaction
| Drug Name | Risk Factors |
|---|---|
|
Amiodarone, Antivirals (Acyclovir, Valacyclovir, Ganciclovir, Ribavirin), isoniazid, nitrofurantoin, Statins (Atorvastatin, Simvastatin, Rosuvastatin, Pravastatin, Lovastatin, Fluvastatin)
|
Concurrent use may increase the chance of peripheral neuropathy
|
|
Antihypertensive (Captopril, Enalapril, Lisinopril, Ramipril, Benazepril, Fosinopril, Quinapril, Perindopril, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, Propranolol, Metoprolol, Atenolol, Carvedilol, Bisoprolol, Nadolol, Amlodipine, Diltiazem, Verapamil, Nifedipine, Nicardipine, Hydrochlorothiazide, Chlorthalidone, Indapamide, Furosemide, Bumetanide, Torsemide, Spironolactone, Amiloride, Triamterene, Prazosin, Doxazosin, Terazosin, Clonidine, Methyldopa, Hydralazine, Minoxidil)
|
Concurrent use increases the chance of hypotension
|
Disease Interaction
Disease Interaction
| Disease Name | Risk Factors |
|---|---|
|
Hypersensitivity
|
Can cause severe allergic reactions
|
Pregnancy
Pregnancy
Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Unopened vials may be stored at controlled room temperature 25º C
Data Sources
Clinical & regulatory information on this page is compiled from the following government sources:
DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.